Transgenomic Enlists PDI to Market Cardiac PGx Test; PDI Entering MDx Space | GenomeWeb

This article has been updated to note that PDI is moving away from the contract sales business with drug companies. Originally published Oct. 22.

Molecular diagnostics firm Transgenomic has partnered with PDI to launch CardioPredict, a pharmacogenetic test that gauges genes associated with response to a number of commonly prescribed drugs for heart conditions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.